Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Contact
walte002@mc.duke.edu(919) 620-5346
Duke Vaccine and Trials Unit-RTP, Duke University PO Box 106008, Durham, NC 27710-6008
View WebsiteAppointment:
Topics:
Countries:
Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.
Publications
-
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, et al. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23;230(3):624–34.Sher LD, Boakye-Appiah JK, Hill S, Wasserman E, Xu X, Maldonado Y, et al. Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds. J Pediatric Infect Dis Soc. 2024 Aug 24;13(8):421–9.Hu X, Karthigeyan KP, Herbek S, Valencia SM, Jenks JA, Webster H, et al. Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine. J Infect Dis. 2024 Aug 16;230(2):455–66.Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, et al. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024 Jun;78(6):1757–68.
See more publications at Scholars@Duke